Streetbeat News

Price Targets

SPRY

Wedbush analyst Andreas Argyrides has maintained an Outperform rating on ARS Pharmaceuticals (NASDAQ:SPRY) and increased the price target from $5 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 2:00 pm

HPQ

Over the past 3 months, 10 Wall Street analysts have provided ratings for HP Inc. (NYSE:HPQ), with an average 12-month price target of $30.7, a high of $39.00, and a low of $23.00. The current average price target represents a 0.97% decrease from the previous average of $31.00. The ratings include 2 bullish, 1 somewhat bullish, 5 indifferent, and 2 somewhat bearish opinions.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:00 pm

CL

Over the past 3 months, 9 Wall Street analysts have published their opinions on Colgate-Palmolive (NYSE:CL), with 4 bullish, 2 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for CL is $81.22, with a high of $87.00 and a low of $73.00, representing a 4.6% decrease from the previous target of $85.14. Analyst ratings are important as they provide investors with insights into stock performance based on research and financial analysis.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:00 pm

KYMR

Kymera Therapeutics (NASDAQ:KYMR) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target among 4 analysts is $32.25, with a high of $38.00 and a low of $24.00. This target suggests a significant 41.1% decrease from the previous target of $54.75. Analysts rate stocks based on future earnings potential and company updates.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:00 pm

ABM

ABM Industries (NYSE:ABM) has received 5 analyst ratings in the last quarter, with an average price target of $43.2, representing an implied upside from the current price of $39.99. The ratings are predominantly indifferent, with 4 out of 5 analysts giving neutral ratings and only 1 somewhat bullish. This average price target is a 20.73% decrease from the previous target of $54.50. Analysts base their ratings on financial predictions and company performance.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:00 pm

COCO

Vita Coco (NASDAQ:COCO) has received 4 analyst ratings in the last quarter, with an average 12-month price target of $31.5, a high of $35.00, and a low of $29.00. The current average price target has decreased by 1.56% from the previous average of $32.00. The ratings include 1 bullish, 1 somewhat bullish, and 2 indifferent, indicating a mixed but slightly positive outlook from analysts.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:00 pm

STZ

Constellation Brands (NYSE:STZ) has received positive analyst ratings in the last quarter, with 5 bullish and 8 somewhat bullish ratings out of 14 total, and one indifferent. The average price target for STZ is $295.64, suggesting a significant upside from the current price of $239.32. This target has increased by 5.1% over the past month. Analyst ratings are based on future earnings and revenue predictions and are updated quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 2:00 pm

IDYA

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and maintained a price target of $43.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:59 pm

ONON

Wedbush analyst Tom Nikic has reiterated an Outperform rating on On Holding (NYSE:ONON) and maintained a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:57 pm

KYMR

Morgan Stanley analyst James Quigley has maintained an Equal-Weight rating on Kymera Therapeutics (NASDAQ:KYMR) but reduced the price target from $37 to $24.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:56 pm